Orphan Drug Lifecycle
What are "orphan drugs" and how their development works.
CRO
Life Science
Regulatory Affairs
Il nostro blog
Analysis of the differences and prospects in the economic and commercial field between Advanced Therapy drugs and traditional drugs
September 18, 2024
Key tools and strategies for the proper marketing of drugs in the countries of the Eurasian Economic Union - EAEU.
September 18, 2024
To simplify the collection of clinical trial data, JSB worked on the development of Counterpoint Software
September 18, 2024
How does the production and supply process change with the advent of Advanced Therapies? The challenges and new scenarios introduced by innovative drugs.
September 18, 2024
The main changes introduced with MDR EU 2017/745: the procedures for obtaining or renewing a certification for Medical Devices.
September 18, 2024
The safety of pesticides: reference standards for drugs of plant origin and other preparations based on medicinal plants
September 18, 2024
For the adaptation to the New Regulations of some Medical Devices, a "Grace Period" is envisaged, a grace period from May 2021 to May 2024.
September 18, 2024
"Orphan" drugs - How and when can a company launch one in Italy? What are the timelines for approval by the competent authorities?
September 18, 2024
The advantages of the new Cold Chain Platform (CCP) for drug monitoring throughout the entire distribution chain.
September 18, 2024
In the first months of 2022, the sixth module of the EUDAMED platform came into force - Further information and general information on the UDI electronic catalog
September 18, 2024